2016 EMAS立场声明:乳腺癌患者骨质疏松的管理

2016-10-06 欧洲女性与男性更年期协会 Maturitas. 2016 Oct 6.

2016年6月,欧洲女性与男性更年期协会(EMAS)发布了乳腺癌患者骨质疏松的管理的立场声明,芳香化酶抑制剂是绝经后雌激素受体阳性乳腺癌患者的一线治疗药物,本文的主要目的是综合早期乳腺癌患者抗骨折治疗的临床试验结果并对乳腺癌患者骨质疏松管理的当前指南进行讨论。主要内容包括:辅助内分泌治疗导致骨质疏松的预防,抗骨吸收药物的应用,当前乳腺癌患者骨质疏松管理指南。

中文标题:

2016 EMAS立场声明:乳腺癌患者骨质疏松的管理

英文标题:

Osteoporosis management in patients with breast cancer: EMAS position statement.

发布日期:

2016-10-06

简要介绍:

2016年6月,欧洲女性与男性更年期协会(EMAS)发布了乳腺癌患者骨质疏松的管理的立场声明,芳香化酶抑制剂是绝经后雌激素受体阳性乳腺癌患者的一线治疗药物,本文的主要目的是综合早期乳腺癌患者抗骨折治疗的临床试验结果并对乳腺癌患者骨质疏松管理的当前指南进行讨论。主要内容包括:辅助内分泌治疗导致骨质疏松的预防,抗骨吸收药物的应用,当前乳腺癌患者骨质疏松管理指南。

拓展指南:骨质疏松相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2016 EMAS立场声明:乳腺癌患者骨质疏松的管理)] GetToolGuiderByIdResponse(projectId=1, id=42c8e1c00132a4b7, title=2016 EMAS立场声明:乳腺癌患者骨质疏松的管理, enTitle=Osteoporosis management in patients with breast cancer: EMAS position statement., guiderFrom=Maturitas. 2016 Oct 6., authorId=null, author=, summary=2016年6月,欧洲女性与男性更年期协会(EMAS)发布了乳腺癌患者骨质疏松的管理的立场声明,芳香化酶抑制剂是绝经后雌激素受体阳性乳腺癌患者的一线治疗药物,本文的主要目的是综合早期乳腺癌患者抗骨折治疗的临床试验结果并对乳腺癌患者骨质疏松管理的当前指南进行讨论。主要内容包括:辅助内分泌治疗导致骨质疏松的预防,抗骨吸收药物的应用,当前乳腺癌患者骨质疏松管理指南。, cover=, journalId=null, articlesId=null, associationId=295, associationName=欧洲女性与男性更年期协会, associationIntro=欧洲女性与男性更年期协会(EMAS)致力于鼓励对女性更年期和男性更年期的相关研究,以及促进专业人士之间的的经验交流。EMAS目的是为整个欧洲的中年男女提供统一的标准化的健康教育和信息。, copyright=0, guiderPublishedTime=Thu Oct 06 00:00:00 CST 2016, originalUrl=, linkOutUrl=, content=2016年6月,欧洲女性与男性更年期协会(EMAS)发布了乳腺癌患者骨质疏松的管理的立场声明,芳香化酶抑制剂是绝经后雌激素受体阳性乳腺癌患者的一线治疗药物,本文的主要目的是综合早期乳腺癌患者抗骨折治疗的临床试验结果并对乳腺癌患者骨质疏松管理的当前指南进行讨论。主要内容包括:辅助内分泌治疗导致骨质疏松的预防,抗骨吸收药物的应用,当前乳腺癌患者骨质疏松管理指南。<br> <br> 拓展指南:<strong>与<font color=red>骨质疏松</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=42c8e1c00132a4b7" title="2016 EMAS立场声明:乳腺癌患者骨质疏松的管理" target=_blank>2016 EMAS立场声明:乳腺癌患者骨质疏松的管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=ac18b1c0013028a1" title="2015 SIGN国家临床指南:骨质疏松的管理和脆性骨折的预防(142)" target=_blank>2015 SIGN国家临床指南:骨质疏松的管理和脆性骨折的预防(142)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=ffb491c0012852b0" title="2016 AACE/ACE临床指南:绝经后骨质疏松症的诊断和治疗" target=_blank>2016 AACE/ACE临床指南:绝经后骨质疏松症的诊断和治疗</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=dd7fd1c0012e870c" title="2015 运动防治骨质疏松专家共识" target=_blank>2015 运动防治骨质疏松专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=79a6b1c00122a66f" title="2016 意大利骨质疏松症的诊断,预防和管理指南" target=_blank>2016 意大利骨质疏松症的诊断,预防和管理指南</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E9%AA%A8%E8%B4%A8%E7%96%8F%E6%9D%BE" target=_blank>有关骨质疏松更多指南</a></ul>, tagList=[TagDto(tagId=285, tagName=乳腺癌), TagDto(tagId=646, tagName=骨质疏松)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=10, categoryName=骨科, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=21067, categoryName=梅斯医学-骨质疏松网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3815, appHits=206, showAppHits=0, pcHits=2640, showPcHits=1668, likes=187, shares=4, comments=5, approvalStatus=1, publishedTime=Sun Nov 06 12:53:34 CST 2016, publishedTimeString=2016-10-06, pcVisible=1, appVisible=1, editorId=5295957, editor=lili, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=lili, createdTime=Sun Nov 06 12:53:34 CST 2016, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 16:06:45 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2016 EMAS立场声明:乳腺癌患者骨质疏松的管理)])
2016 EMAS立场声明:乳腺癌患者骨质疏松的管理
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=154706, encodeId=fb0a154e0629, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Nov 10 07:29:09 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154258, encodeId=0cbc154258de, content=很好,不错,以后会多学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Nov 08 08:12:54 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154143, encodeId=af0d1541430d, content=学习了 非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161105/IMG581CB0FB0DDD47343.jpg, createdBy=a8021976392, createdName=1e171f5bm53(暂无匿称), createdTime=Mon Nov 07 18:25:48 CST 2016, time=2016-11-07, status=1, ipAttribution=)]
    2016-11-10 李东泽

    这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=154706, encodeId=fb0a154e0629, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Nov 10 07:29:09 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154258, encodeId=0cbc154258de, content=很好,不错,以后会多学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Nov 08 08:12:54 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154143, encodeId=af0d1541430d, content=学习了 非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161105/IMG581CB0FB0DDD47343.jpg, createdBy=a8021976392, createdName=1e171f5bm53(暂无匿称), createdTime=Mon Nov 07 18:25:48 CST 2016, time=2016-11-07, status=1, ipAttribution=)]
    2016-11-08 李东泽

    很好,不错,以后会多学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=154706, encodeId=fb0a154e0629, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Nov 10 07:29:09 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154258, encodeId=0cbc154258de, content=很好,不错,以后会多学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Nov 08 08:12:54 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154143, encodeId=af0d1541430d, content=学习了 非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161105/IMG581CB0FB0DDD47343.jpg, createdBy=a8021976392, createdName=1e171f5bm53(暂无匿称), createdTime=Mon Nov 07 18:25:48 CST 2016, time=2016-11-07, status=1, ipAttribution=)]
    2016-11-07 1e171f5bm53(暂无匿称)

    学习了 非常感谢

    0